Comments on: Patritumab deruxtecan by Daiichi Sankyo for Fallopian Tube Cancer: Likelihood of Approval /data-insights/patritumab-deruxtecan-daiichi-sankyo-fallopian-tube-cancer-likelihood-of-approval/ The leading site for news and procurement in the pharmaceutical industry Mon, 09 Sep 2024 07:12:37 +0000 hourly 1 https://wordpress.org/?v=6.6.2